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According to the World Health Organization (WHO), one of the milestones set by the London
Declaration for Chagas disease—the interruption of Chagas disease transmission through
blood transfusion in Latin America—was achieved in most countries (20 out of 21) in 2015
[1]. This is a crucial step towards reaching the goal of controlling Chagas disease by 2020.
However, many challenges remain: less than 1% of the 6 to 7 million people infected with Try-
panosoma cruzi are treated, and new infections still occur [2].
Twenty to thirty percent of chronic Chagas disease patients will develop cardiac and/or gas-
trointestinal complications [3]. The WHO recommends treating T. cruzi-infected patients.
Antiparasitic treatments are highly effective in patients in the acute phase and reduce the risk
of disease progression in patients in the indeterminate stage of the disease (patients chronically
infected with T. cruzi but without evidence of cardiac or gastrointestinal disease) [4,5]. Because
T. cruzi can be transmitted by a variety of routes [6] (i.e., vectorial transmission when T. cruzi
parasites, which are released when the infected blood-sucking triatomine bugs defecate, enter
the body via the skin break caused by the bug’s bite or via other mucosa [e.g., oral transmission
through contaminated food]; congenital infection; blood transfusion; and cell, blood, or tissue
transplantation) and because the majority of people with chronic infection have never been
tested and are not aware of their status, the development of new tools to diagnose Chagas dis-
ease is a priority. This is true in endemic countries as well as in regions where infected people
have migrated in recent years (e.g., Europe, Asia, and North America). Despite concerted
efforts to use available tools to diagnose Chagas disease in different patient groups and epide-
miological and clinical settings in Latin American countries over the last four decades, and in
nonendemic countries since the early 2000s, a large number of patients are diagnosed late or
not at all. While the reasons for these diagnostic trends are diverse and vary across countries
and patient groups, one of the main limitations is the lack of reliable diagnostic tests adapted
to the needs of patients and health systems.
The resources to develop new diagnostic tools for Chagas disease are scarce, so it is impor-
tant to allocate them to diagnostic needs that are not adequately covered by existing tools.
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Agreeing on diagnostic priorities will help to ensure that efforts and resources are directed to
the development of tests that increase access to diagnosis and contribute to disease control. In
recent years, the WHO, the Pan American Health Organization (PAHO), and Chagas disease
experts have initiated this important process by identifying a range of diagnostic needs [7–11]
(summarised in Table 1). The next step is for the Chagas disease community, including profes-
sionals with different backgrounds, expertise, and geographical locations, to rank these diag-
nostic needs.
To facilitate this ranking of diagnostic needs, we invited 155 Chagas disease experts to iden-
tify the three main diagnostic priorities for Chagas disease from Table 1. The experts were
selected from among lead authors of Chagas disease scientific papers, physicians managing
Chagas disease patients, and representatives of institutions involved in Chagas disease man-
agement (i.e., ministries of health, nongovernmental organizations [NGOs], private-public
partnerships [PPP], the WHO/PAHO, and industry). Eighty-six of the experts (55%) were
from Latin American countries; the other 69 (45%) were from nonendemic countries. Details
on the 155 experts invited to participate are provided in S1 Table. The experts were asked to
take into account the following: (1) existing diagnostic tools and (2) the expected clinical and
epidemiological scenario of Chagas disease in the next five years. The survey was conducted in
English, Spanish, and Portuguese in May and June of 2016 using Google Forms. For each
expert, 3 points, 2 points, and 1 points were given to the first-, second-, and third-most-impor-
tant priorities, respectively. A final score, calculated for each diagnostic need, was used to rank
them. The results of the survey are presented here, pooled as well as by subgroup.
Sixty-two experts (40%) completed the survey; the respondents were equally distributed
(n = 31) between Latin American and non-Latin American countries. The majority worked in
research (n = 22) and hospitals or NGOs (n = 16), but respondents also included representa-
tives of health ministries and the WHO/PAHO (n = 9) and patient associations (n = 1), among
Table 1. Diagnostic needs for Chagas disease.
Diagnostic need Definition
Point-of-care* (PoC) test for Chagas disease
patients in the acute phase
PoC test to identify acute T. cruzi infection (e.g., vector,
oral transmission in the general population, reactivation
in immunosuppressed patients).
PoC test for Chagas disease patients in the
chronic phase
PoC test to identify chronic T. cruzi infection in the
general population (including pregnant women).
Test to screen blood and organ donors/donations Test to screen for T. cruzi infection in blood and organ
donors/donations.
PoC test for congenital Chagas disease PoC test to detect T. cruzi in newborns (as a result of
congenital transmission of Chagas Disease).
Test for early assessment of treatment response Test to assess efficacy of antiparasitic treatment soon
after completion of treatment in the chronic phase.
Progression test: Test to identify patients with a
high risk of developing Chagas disease
complications
Test to identify, among T. cruzi infected patients,
individuals with a high risk of developing neurologic,
cardiac, or intestinal complications.
Test for early assessment of heart damage in
Chagas disease patients
Test to identify, among T. cruzi infected patients, those
with early cardiac damage.
Test for early assessment of digestive damage in
Chagas disease patients
Test to identify, among T. cruzi infected patients, those
with early digestive damage.
Test for screening of drug resistance to
benznidazole and/or nifurtimox
Test to determine if T. cruzi is resistant to the available
drugs (benznidazole/nifurtimox).
*A point-of-care (PoC) test is a test performed and interpreted where health care is provided, close to or
near the patient.
doi:10.1371/journal.pntd.0005148.t001
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others (see S1 Table for details). The response rate was higher among experts from non-Latin
American countries (45%) compared to Latin American experts (36%). As detailed in Table 2,
four diagnostic needs obtained similar scores: (1) a test for early assessment of treatment
response (score 83); (2) a point-of-care (PoC) test for congenital Chagas disease (score 76); (3)
a progression test to identify patients with a high risk of developing Chagas disease complica-
tions (score 73); and (4) a PoC test for Chagas disease patients in the chronic phase (score 67).
The different subgroups (e.g., Latin American versus non-Latin American experts, different
areas of expertise) consistently identified the same four diagnostic priorities for Chagas
disease.
Experts from Latin America ranked the PoC test for congenital Chagas disease (score 38) as
their top priority, whilst those from non-Latin American countries ranked the test for early
assessment of treatment response (score 48) in first place. Researchers identified the progres-
sion test as the first priority, unlike respondents working in hospitals, NGOs, health ministries,
and the WHO/PAHO, for whom the test to assess treatment response was the first priority.
The rest of the diagnostic needs listed had lower scores (ranging from 1 to 28), and there were
no major differences between subgroups, with one exception: the score for the PoC test for
Chagas disease patients in the acute phase received a relatively high score from participants in
Latin America (score 26) compared to non-Latin American experts (score 2). The complete
dataset, including the scores for all diagnostic needs, is provided as supplementary material
(S1 and S2 Tables).
According to respondents, the diagnostic tools currently available meet the requirements of
some diagnostic needs, e.g., screening blood and organ donors or diagnosing Chagas disease
patients in the acute phase. However, new diagnostic tools should be developed to assess treat-
ment response, diagnose congenital Chagas disease, identify individuals at risk of developing
Chagas disease-related complications, and diagnose T. cruzi infected individuals in the chronic
phase. The development of those tools should be guided by detailed Target Product Profiles
(TPPs) developed and endorsed by the WHO and the Chagas disease community. The current
TPPs for Chagas disease diagnostics [8,12] should be reviewed and expanded to ensure they
cover the priorities identified in this survey. The results of this survey and the revised TPPs
should guide research groups and attract public and private funders interested in developing
diagnostic tools for Chagas disease with the highest public health impact.
Defining the diagnostic needs and priorities for Chagas disease should be a dynamic pro-
cess that is open to the whole Chagas disease community. To maximise input, the form used to
Table 2. Ranking diagnostic needs for Chagas disease (June 2016).
Diagnostic need Total Latin
America
Non-Latin
America
Researchers Hospitals/
NGOs
MoH—WHO/
PAHO1
Number of respondents 62 31 31 22 16 9
Rank
(score)
Rank
(score)
Rank (score) Rank (score) Rank (score) Rank (score)
Test for early assessment of treatment response 1 (83) 3 (35) 1 (48) 2 (25) 1 (26) 2 (14)
PoC2 test for congenital Chagas disease 2 (76) 1 (38) 3 (38) 3 (24) 4 (16) 1 (15)
Progression test: test to identify patients with a high risk of
developing Chagas disease complications
3 (73) 4 (29) 2 (44) 1 (29) 2 (24) 4 (5)
PoC test for Chagas disease patients in the chronic phase 4 (67) 2 (36) 4 (31) 4 (18) 3 (19) 3 (12)
1MoH, Ministry of Health; WHO, World Health Organization; PAHO, Pan American Health Organization;
2PoC, Point of care
doi:10.1371/journal.pntd.0005148.t002
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collect the data presented in this paper will remain available at http://goo.gl/forms/
66jt8cLxShAyXbm33 for six months from the date of publication.
Supporting Information
S1 Table. Individual ranking of the nine diagnostic needs for Chagas disease conducted by
62 experts. For each expert, 3 points, 2 points, and 1 point were given to the first, second, and
third priorities, respectively.
(DOCX)
S2 Table. Ranking and scores for all diagnostic needs for Chagas Disease.
(DOCX)
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